Combined Granular-Lattice Corneal Dystrophy Type 2

Combined Granular-Lattice Corneal Dystrophy Type 2 is an inherited corneal dystrophy caused most commonly by the R124H mutation in the TGFBI (TGFBIp) gene. Abnormal protein deposits form in the clear front window of the eye (the cornea). Early on, small white “crumb-like” spots appear in the central cornea; as the condition advances, diffuse haze and recurrent corneal erosions cause pain, glare, and blurred vision. The disease is autosomal dominant—family members can carry the mutation even if their eyes look normal. Refractive laser procedures (e.g., LASIK) can provoke dramatic worsening and are considered contraindicated in confirmed or suspected GCD2. JAMA Network+4PMC+4PMC+4

Combined granular-lattice corneal dystrophy type 2 is a genetic eye disease that changes the clear front window of the eye (the cornea). Tiny protein deposits build up in the cornea over time. Two kinds of deposits appear together:

• Granular (hyaline) deposits that look like small, white crumbs or snowflakes.

• Lattice (amyloid) lines that look like thin, branching threads.

Because both patterns show up in the same cornea, doctors call it a “combined” dystrophy. The deposits usually begin in the central cornea and spread slowly. Early on you may see glare, light sensitivity, or mild blur. Later, the cornea can develop recurrent corneal erosions (the surface rubs off easily), which cause eye pain, tearing, and more blur. The disease is inherited in an autosomal dominant way, so a parent with the faulty gene can pass it to a child. The usual genetic change is a p.Arg124His mutation in the TGFBI gene. This gene tells the cornea how to make a support protein; the mutation makes that protein misfold and form deposits. PMC+2PubMed+2

People with one copy of the mutation tend to have milder disease that starts in late childhood or adulthood. People with two copies (homozygous) often have earlier, faster, and more severe disease, with quicker return of deposits even after surgery. PubMed+1

Other names

• Avellino corneal dystrophy

• Granular corneal dystrophy type 2 (GCD2)

• Combined granular-lattice corneal dystrophy

• TGFBI-associated corneal stromal dystrophy (group label) EyeWiki+2EyeWiki+2

Types

Doctors sometimes group GCD2 by pattern and genetics:

1. Classic heterozygous GCD2 – one TGFBI mutation (usually p.Arg124His). On slit-lamp exam you see central white granular spots with clear gaps between them. With time, lattice-like lines and haze appear. Symptoms are often mild at first. PMC+1

2. Homozygous GCD2 – two copies of the mutation. This form starts early, progresses quickly, and often recurs fast after corneal procedures. PubMed

3. Phenotypic spectrum / overlap – even in one family, some eyes look more granular, others show more lattice lines. That variability is typical for autosomal-dominant TGFBI diseases. disorders.eyes.arizona.edu

4. Post-refractive surgery acceleration – after LASIK/PRK/SMILE, deposits can rapidly worsen and symptoms can flare. This is why laser vision correction is generally contraindicated in known or suspected TGFBI dystrophy. PubMed+2PMC+2

Causes

In this disease, the root cause is genetic. The items below explain the genetic driver, disease mechanisms, and real-world triggers/modifiers that can worsen or unmask symptoms.

1. TGFBI mutation (p.Arg124His) – This is the main cause of GCD2. It makes a corneal protein misfold and build up as granular and lattice deposits. PMC

2. Other TGFBI variants – Less often, other changes in the same gene can create combined granular-lattice patterns or related stromal dystrophies. PubMed+1

3. Autosomal dominant inheritance – One mutated copy is enough to cause disease. Risk to each child is about 50%. Genetic Diseases Info Center

4. Homozygosity – Having two mutated copies leads to earlier onset, denser deposits, and faster recurrence after surgery. PubMed

5. Protein misfolding and aggregation – The abnormal TGFBI protein tends to clump in the corneal stroma, forming the visible opacities. PubMed

6. Amyloid formation – Part of the deposits convert into amyloid, which forms the lattice lines. Special stains like Thioflavin-T highlight this in tissue. PMC

7. Age (time) – Deposits usually increase over decades, so vision symptoms slowly rise with age. PubMed

8. Microtrauma to the cornea – Everyday minor rubbing or injuries can trigger erosions or make symptoms more noticeable. (This is common in corneal dystrophies generally.) National Organization for Rare Disorders

9. Refractive laser surgery (LASIK) – Creates a flap and can accelerate deposits and erosions; strongly discouraged in TGFBI dystrophies. PubMed+1

10. Surface ablation (PRK/LASEK) – Can also worsen deposits; recurrences are reported even with Mitomycin-C. eyerounds.org

11. SMILE – First reports show exacerbation can occur after SMILE, too. Lippincott Journals

12. Inflammation after surgery – Post-surgical inflammation may promote deposit growth in susceptible corneas. Ajo

13. Epithelial stress – Research suggests the epithelium helps drive the accelerated deposits after LASIK. ScienceDirect

14. Modifier genes / variable penetrance – Some families show reduced penetrance and varied expressivity, so genes and environment modify how strongly the disease shows. PMC

15. Ultraviolet light exposure – UV can stress corneal tissue and may worsen haze or symptoms over many years (general corneal biology; used here as a plausible modifier).

16. Dry eye – A dry surface increases friction and can trigger erosions, making pain and blur more frequent. (General corneal evidence; common with erosions.)

17. Contact lens overwear – Can increase surface microtrauma and discomfort in eyes prone to erosions.

18. Eye rubbing – Mechanical stress may precipitate erosion episodes in a fragile epithelium.

19. Infections or inflammation – Any keratitis or inflammation can aggravate symptoms in a dystrophic cornea.

20. Hormonal and systemic stressors – Illness, poor sleep, or systemic inflammation can lower the threshold for erosion symptoms (non-specific modifiers seen in recurrent erosion care).

Symptoms

1. Blurry vision that comes and goes, worse in bright light. Early blur may be mild. Later blur can be steady. PMC

2. Glare and halos, especially at night or with oncoming headlights. PentaVision

3. Light sensitivity (photophobia) – bright light hurts or makes you squint. Johns Hopkins Medicine

4. Recurrent corneal erosions (RCE) – sudden sharp pain, tearing, and inability to open the eye, often on waking in the morning. PMC

5. Foreign-body sensation – the eye feels scratchy or gritty.

6. Redness and tearing during erosion attacks.

7. Fluctuating vision – good days and bad days, especially after erosions heal and break down again.

8. Decreased contrast sensitivity – print may look washed out, especially in low light.

9. Reduced best-corrected vision over time as deposits and haze increase. PMC

10. Dry-eye-like discomfort – burning or stinging from surface instability.

11. Headache or eye strain from squinting to see clearly.

12. Ghosting/diplopia in one eye due to irregular anterior cornea.

13. Slow healing after corneal irritation or small injuries.

14. Frequent need to change glasses as surface irregularity alters refraction.

15. Post-refractive surgery flare – rapid worsening of deposits and symptoms if LASIK/PRK/SMILE was done before the diagnosis. PubMed+1

Diagnostic tests

A) Physical examination (clinic exam and bedside checks)

1. History and family history – Ask about eye pain on waking, glare, and relatives with similar eye problems. This points to a genetic corneal dystrophy. Genetic Diseases Info Center

2. Visual acuity – Measures how clearly you see. It tracks impact on vision as deposits and haze increase over years. PMC

3. Pinhole test – A simple handheld test. If vision improves through the pinhole, blur is more likely from the front of the eye (cornea) rather than from retina.

4. Refraction (glasses check) – Finds the best spectacle power and reveals irregular astigmatism from surface changes.

5. Slit-lamp biomicroscopy – The key exam. The doctor shines a thin light beam to see granular spots, lattice lines, and haze in the stroma. EyeWiki

6. Fluorescein staining – A special dye highlights surface defects during an erosion and helps confirm RCE.

7. Corneal sensitivity (Cochet–Bonnet esthesiometer) – Touch testing checks nerve function, which can be altered in diseased or post-surgical corneas.

8. Intraocular pressure – Routine safety check; not diagnostic for GCD2 but done in a full exam.

B) Manual / chairside functional tests

9. Contrast sensitivity – Measures how well you see shades of gray; often reduced with haze and scatter.

10. Glare testing – Simulates bright light; shows functional vision loss from forward scatter.

11. Tear break-up time and ocular surface evaluation – Looks for dry eye, which can trigger erosions and worsen comfort.

12. Photostress recovery time – After bright light, measures how fast vision returns; longer times reflect scatter and surface issues.

C) Laboratory and pathological tests

13. Genetic testing for TGFBI – A blood or saliva test confirms the mutation (commonly p.Arg124His). This is very helpful for diagnosis, family counseling, and screening before refractive surgery. Clinical labs and registries list available tests. NCBI

14. Corneal tissue histology (if tissue is removed) – Under the microscope, hyaline deposits stain with Masson trichrome, and amyloid stains with Congo red or Thioflavin-T. This proves the combined granular-lattice nature. PMC

15. Immunohistochemistry for TGFBIp – Shows abnormal protein accumulation in the stroma. (Used in research and some pathology labs.) eyerounds.org

D) Electrodiagnostic tests (to rule out other causes of poor vision)

16. Visual evoked potentials (VEP) – Checks the optic pathway. Usually normal in GCD2; used to exclude nerve/brain causes when vision is worse than the cornea alone explains.

17. Full-field electroretinogram (ERG) – Checks retina function. Usually normal in GCD2; helps rule out retinal disease if the picture is unclear.

18. Electro-oculogram (EOG) – Rarely needed; part of a full work-up when vision loss seems out of proportion.

(Electrodiagnostics are not required in typical cases; they are for confusing situations when doctors need to be sure the problem is not in the retina or brain.)

E) Imaging tests

19. Anterior segment OCT (AS-OCT) – Cross-section images show location and depth of deposits and surface irregularity, and help plan treatment. It also helps detect subtle post-surgery changes. PubMed

20. In-vivo confocal microscopy – High-magnification “virtual biopsy” that can visualize granular and lattice deposits in living corneas. (Common in tertiary centers.)

21. Scheimpflug tomography / corneal topography – 3-D maps show shape irregularity and haze; useful for monitoring and for pre-operative screening to avoid refractive surgery if GCD2 is suspected. PubMed

22. Pachymetry and specular microscopy – Measure corneal thickness and endothelial cell health; helpful before and after procedures like phototherapeutic keratectomy (PTK) or keratoplasty.

Non-pharmacological treatments (therapies & others)

These measures ease symptoms, protect the surface, and delay surgery. None “cures” the dystrophy.

1. Education & genetic counseling (simple explanation)
   Explain the inherited nature of GCD2, the tendency for recurrence after surgery, and the risk of post-LASIK exacerbation. Offer cascade testing for relatives where available; this also prevents inappropriate refractive surgery in asymptomatic carriers. Nature+1

2. Avoid LASIK/PRK for refractive purposes
   Laser refractive surgery can unmask or accelerate GCD2, causing rapid deposit buildup in the flap interface and large drops in vision. Patients with known or suspected GCD2 should avoid LASIK/PRK for refractive correction. PMC+2JAMA Network+2

3. Frequent preservative-free lubricating drops
   Non-medicated artificial tears reduce friction, soothe burning, and lower the chance of erosions. Use preservative-free vials to avoid toxicity in frequent users; apply as needed through the day. (General corneal surface care guidance.) PMC

4. Lubricating gel or ointment at bedtime
   A bland gel/ointment at night lowers nocturnal friction that triggers erosions, improving morning comfort and sleep. PMC

5. Hypertonic saline gel/ointment at night (surface protection)
   Used off-label in dystrophies to reduce epithelial edema and morning symptoms in erosions; apply at bedtime to the affected eye(s). (Adjunctive surface measure in corneal disease.) PMC

6. Bandage soft contact lens (BCL)
   A high-oxygen, extended-wear bandage lens shields the epithelium as it heals after an erosion, reducing pain and allowing better blinking. Requires close follow-up to minimize infection risk. PMC

7. Scleral (vault) lens fitting
   A large rigid lens that vaults the cornea can improve visual acuity by creating a new smooth optical surface over irregular deposits and haze, while maintaining a liquid reservoir for comfort. PMC

8. Punctal occlusion (temporary plugs)
   In patients with evaporative or aqueous-deficient dry eye symptoms, punctal plugs help retain natural and artificial tears, improving comfort and reducing erosions. PMC

9. Moisture chamber glasses & humidifier
   Simple environment changes—wraparound glasses and room humidification—reduce tear evaporation and surface stress that exacerbate pain and erosions. PMC

10. Lid hygiene & warm compresses
    Treating meibomian gland dysfunction (MGD) improves the lipid layer of the tear film, stabilizing the surface and cutting friction over dystrophic deposits. PMC

11. Pain control with cold compresses & oral analgesics
    During acute erosions, non-prescription systemic analgesics and cold compresses provide symptomatic relief while the epithelium re-seals. PMC

12. Short in-office debridement (for large erosions)
    A clinician may gently lift loose epithelium and smooth the surface under sterile conditions, then place a BCL; this speeds healing and reduces recurrent snag points. PMC

13. Anterior stromal puncture (selected cases)
    Tiny, patterned stromal nicks (outside the central visual axis) can promote firmer epithelial adhesion in eyes with recurrent erosions not responding to conservative care. PMC

14. Phototherapeutic keratectomy (PTK)
    An excimer laser gently polishes the anterior stroma, smoothing deposits/haze and improving vision and pain—but recurrence is common within months to years, sometimes requiring repeat PTK. PubMed+1

15. Topography-guided laser smoothing (select centers)
    Some surgeons combine PTK with topography guidance to optimize the optical zone and reduce induced irregularity; recurrence remains the main limitation. Lippincott Journals

16. Deep anterior lamellar keratoplasty (DALK)
    When deposits and haze are deep and visual acuity falls, DALK replaces diseased front stromal layers while preserving endothelium. Recurrence can still happen in the graft. PMC+1

17. Penetrating keratoplasty (full-thickness transplant, PK)
    Reserved for severe opacity or scarring; improves clarity but GCD2 frequently recurs in grafts over time, so careful, long-term follow-up is needed. PubMed+1

18. Femtosecond-assisted anterior lamellar keratoplasty
    A femtosecond laser can craft precise donor-host cuts for smoother interfaces; used when PTK is insufficient and a lamellar approach is preferred. EyeWiki

19. Avoid ocular surface triggers (smoke, desiccating environments, dusty air)
    Minimizing irritants lowers inflammation and erosions, improving daily comfort and reducing need for medications. PMC

20. Regular follow-up and photography
    Serial slit-lamp photos/topography document progression and time-to-recurrence after PTK or keratoplasty, supporting timely retreatment decisions. PubMed+1

---

Drug treatments

Important: No drug is FDA-approved to cure or stop GCD2. Medicines below are supportive or peri-procedural (e.g., for dry eye, inflammation, erosions, or infection risk). Indications come from each drug’s FDA label; use in GCD2 is off-label unless otherwise stated. Always prescribe/monitor under an ophthalmologist.

1. Cyclosporine 0.05% ophthalmic emulsion (RESTASIS / Restasis Multidose)
   Class: Topical calcineurin inhibitor (immunomodulator). Dose/Time: 1 drop BID in each eye (about 12 hours apart). Purpose: Increase tear production in inflammatory dry eye to reduce friction over dystrophic epithelium. Mechanism: Blocks T-cell activation and cytokines on the ocular surface, improving tear film stability. Side effects: Transient burning, redness. Label evidence: Indicated for keratoconjunctivitis sicca; not specifically for GCD2. FDA Access Data+1

2. Lifitegrast 5% ophthalmic (XIIDRA)
   Class: LFA-1 antagonist (anti-inflammatory). Dose: 1 drop BID ~12 hours apart. Purpose: Reduce dry-eye inflammation and symptoms that aggravate erosions. Mechanism: Inhibits LFA-1/ICAM-1 binding, dampening T-cell–mediated surface inflammation. Side effects: Dysgeusia, irritation, blurry vision. Label evidence: Approved for signs/symptoms of dry eye disease. FDA Access Data+1

3. Loteprednol etabonate 0.5% ophthalmic (LOTEMAX, gel/ointment)
   Class: Topical corticosteroid. Dose: Typically QID short courses under physician guidance. Purpose: Calm acute surface inflammation after erosions or post-procedure. Mechanism: Glucocorticoid anti-inflammatory activity with soft-steroid design. Side effects: IOP rise, delayed healing, infection risk—short, monitored use only. Label evidence: Indicated for post-operative inflammation/pain; off-label for erosions in dystrophy. FDA Access Data+1

4. Fluorometholone 0.1% (FML / FLAREX 0.1% acetate)
   Class: Topical corticosteroid. Dose: Short taper—e.g., QID → BID as directed. Purpose: Reduce inflammation and pain with recurrent erosions or post-PTK. Mechanism: Inhibits inflammatory mediators. Side effects: IOP rise, infection risk; monitor. Label evidence: Steroid-responsive ocular inflammation. FDA Access Data+1

5. Prednisolone acetate 1% (PRED FORTE)
   Class: Topical corticosteroid. Dose: Typically QID then taper, supervised. Purpose: Calm post-PTK/post-keratoplasty inflammation. Mechanism: Potent steroid effect on cytokines/cells. Side effects: IOP spike, cataract risk; use with monitoring. Label evidence: Steroid-responsive anterior segment inflammation. FDA Access Data

6. Ketorolac 0.5% ophthalmic (ACULAR)
   Class: Topical NSAID. Dose: Per label for post-op inflammation/itching. Purpose: Short-term pain relief after debridement/PTK; not for chronic use due to epithelial risk. Mechanism: COX inhibition reduces prostaglandins. Side effects: Stinging; rare corneal complications—avoid prolonged use on compromised epithelium. Label evidence: Post-cataract inflammation / allergic itch. FDA Access Data+1

7. Moxifloxacin 0.5% ophthalmic (VIGAMOX)
   Class: Topical fluoroquinolone antibiotic. Dose: Per label—e.g., TID for bacterial conjunctivitis; often used peri-PTK off-label for prophylaxis. Purpose: Reduce infection risk with epithelial defects/BCL. Mechanism: DNA gyrase/topoisomerase inhibition. Side effects: Irritation, hypersensitivity. Label evidence: Bacterial conjunctivitis. FDA Access Data+1

8. Levofloxacin ophthalmic (IQUIX 1.5% / QUIXIN 0.5%)
   Class: Fluoroquinolone antibiotic. Dose: Per label. Purpose: Similar peri-defect prophylaxis. Mechanism/Side effects: As above. Label evidence: Bacterial conjunctivitis/keratitis indications vary by product. FDA Access Data+1

9. Tobramycin/dexamethasone (TOBRADEX ST)
   Class: Antibiotic + steroid combo. Dose: Short courses post-procedure under close supervision. Purpose: Post-PTK comfort with infection prophylaxis. Mechanism: Aminoglycoside + steroid. Side effects: IOP rise, delayed healing; use judiciously. Label evidence: Combination anti-infective/anti-inflammatory ophthalmic agent. FDA Access Data+1

10. Doxycycline (oral; various brands e.g., DORYX, ACTICLATE)
    Class: Tetracycline antibiotic with MMP-modulating properties. Dose: Common ocular-surface regimens use low-dose courses (off-label). Purpose: For stubborn recurrent erosions with meibomian dysfunction—reduces matrix metalloproteinases, stabilizes epithelium. Side effects: Photosensitivity, GI upset; avoid in pregnancy/children. Label evidence: Systemic infections (approved); ocular MMP modulation is off-label. FDA Access Data+1

11. Cenegermin 0.002% (OXERVATE)
    Class: Recombinant human nerve growth factor (biologic). Dose: One drop 6× daily for 8 weeks (per label) in neurotrophic keratitis. Purpose in GCD2: Not indicated for GCD2, but may be considered off-label if severe erosions lead to neurotrophic changes and poor healing. Side effects: Eye pain, hyperemia. Label evidence: Approved for neurotrophic keratitis (NK) only. FDA Access Data+1

12. Short-course topical antibiotic prophylaxis (class concept)
    Examples: Ofloxacin/levofloxacin/moxifloxacin per label if an erosion leaves the cornea open, or after debridement/PTK. Purpose/Mechanism/Side effects: As for items 7–8; use briefly to lower infection risk until the epithelium closes. FDA Access Data+1

13. Post-keratoplasty steroid taper (class concept)
    Agents: Prednisolone acetate, loteprednol, fluorometholone per clinician protocol. Purpose: Prevent graft inflammation and rejection while balancing recurrence risk. Evidence: Standard graft care; recurrence in grafts remains a problem in GCD2. PubMed+1

14. Topical antihistamine/mast-cell stabilizer (comfort adjunct)
    If ocular allergy worsens rubbing/irritation, a doctor may add an anti-allergy drop to reduce itch and mechanical stress. (Label indications vary by product.) PMC

15. Hypertonic saline 5% ophthalmic (symptom aid)
    Often used off-label to reduce epithelial edema and morning stickiness in erosions; available OTC or Rx depending on region. (General surface measure.) PMC

16. Cycloplegic drops (short-term, in severe erosions)
    To relieve ciliary spasm pain, clinicians may briefly use a cycloplegic; dosing individualized. (General corneal injury care.) PMC

17. Topical anesthetics (strictly in-office only)
    Not for home use (delays healing/toxicity). In the clinic they aid procedures such as debridement or bandage lens placement. PMC

18. Topical NSAIDs (peri-procedural only)
    Short, carefully limited use after PTK to reduce pain, avoiding chronic application to compromised epithelium. (See ketorolac label.) FDA Access Data

19. Antiviral prophylaxis (if indicated by history)
    Not routine for GCD2, but if a patient has concurrent HSV keratitis history around surgeries, clinicians may follow standard HSV prophylaxis protocols. (General corneal surgery practice.) PMC

20. Preservative-free tear substitutes (various)
    Though not “drugs” with NDAs, high-quality, preservative-free lubricants are backbone therapy to minimize erosions and symptoms. PMC

Why only a few true FDA-label documents appear above: Many core agents in day-to-day surface care (e.g., artificial tears, some hypertonic preparations) are sold as OTC medical devices or non-NDA products and therefore don’t have Drugs@FDA labels; I therefore cite the FDA labels where they exist (e.g., cyclosporine, lifitegrast, ketorolac, steroids, fluoroquinolones) and explicitly flag off-label support where appropriate. FDA Access Data+4FDA Access Data+4FDA Access Data+4

---

Dietary molecular supplements

There is no supplement proven to stop GCD2. Some options target dry-eye–type symptoms to reduce surface stress. Discuss with your clinician to avoid interactions.

1. Omega-3 fatty acids (EPA/DHA)
   Omega-3s may improve dry eye symptoms for some people, though results are mixed across trials; benefits likely relate to anti-inflammatory effects on meibomian glands and tear film. Typical doses range 1–3 g/day EPA+DHA, with meals. Watch for anticoagulation interactions. PubMed+2Office of Dietary Supplements+2

2. Omega-3 topical research
   Topical omega-3 is experimental; reviews suggest possible symptom benefit in dry eye but evidence is limited—consider only within a clinician’s plan. MDPI

3. Vitamin C (ascorbic acid)
   An antioxidant cofactor for collagen; adequate dietary intake supports general corneal healing after erosions or procedures. Take dietary RDA unless supervised for higher doses. (Adjunctive rationale.) PMC

4. Vitamin D (optimize deficiency)
   Low vitamin D is linked with ocular surface discomfort in some studies; correcting deficiency can support overall ocular surface health. Supplement per clinician after blood testing. PMC

5. Hydration & electrolyte balance
   Adequate water and balanced electrolytes support tear production and comfort; simple, safe baseline for any corneal surface disease. PMC

6. Antioxidant-rich diet (leafy greens, colorful fruits)
   A diet rich in antioxidants helps mitigate oxidative stress at the ocular surface—useful for symptom control though not disease-modifying. PMC

7. Flaxseed oil (ALA source)
   Plant-based omega-3 (ALA) may contribute to anti-inflammatory lipid profiles; typical doses 1–2 g/day, with variable conversion to EPA/DHA. Evidence is weaker than fish-oil trials. Office of Dietary Supplements

8. Warm-compress routines (supports meibum quality)
   While not a “molecule,” routine heat therapy improves meibum flow and tear stability, reducing friction over deposits. Combine with lid hygiene. PMC

9. Balanced dietary lipids (less trans-fat, adequate omega-3/6)
   Reducing pro-inflammatory dietary fats and ensuring omega-3 intake may support tear film function. ScienceDirect

10. Clinical nutrition follow-up
    Registered dietitian input helps align supplements, overall diet, and any systemic conditions affecting ocular surface (e.g., autoimmune dryness). PMC

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved stem-cell drugs for GCD2. A few therapies support healing when erosions become hard to close; use is chosen case-by-case.

1. Cenegermin (OXERVATE) — neurotrophic rescue
   For eyes that develop neurotrophic keratitis (poor corneal sensation and non-healing defects), cenegermin can restore epithelial integrity by stimulating nerve growth and healing. Dose: 1 drop 6×/day for 8 weeks per FDA label. Not a GCD2 cure. FDA Access Data

2. Autologous serum tears (AST)
   Not FDA-approved, prepared from the patient’s blood; rich in growth factors and vitamins that promote epithelial healing in recalcitrant erosions. Consider when standard therapy fails. (Clinical practice rationale in surface disease.) PMC

3. Platelet-rich plasma (PRP) tears
   Like AST, PRP provides concentrated platelet-derived growth factors for epithelial repair; made in specialized compounding settings. PMC

4. Aminergic/peptidergic experimental drops (investigational)
   Some centers explore investigational growth-factor or peptide drops for non-healing epithelium; these are research-stage and not standard of care. PMC

5. Post-graft steroid regimens (rejection prevention)
   While not “regenerative,” appropriate topical steroid tapers protect graft clarity after DALK/PK and indirectly support visual rehabilitation; dosing individualized. PMC

6. Future directions (gene-/protein-targeted approaches)
   Preclinical work in TGFBI R124H models aims to clarify pathogenesis; human gene or protein therapies for GCD2 remain investigational. PLOS+1

---

Surgeries

1. Phototherapeutic Keratectomy (PTK)
   What: Excimer laser polishing of the anterior stroma. Why: Improve vision and reduce pain by smoothing or removing superficial deposits/haze. Caveat: High recurrence—often within 1–3 years; repeat PTK is common. PubMed+1

2. Topography-guided laser smoothing
   What: Laser ablation guided by corneal maps. Why: Enhance optical quality when irregularity contributes to blur; still subject to recurrence. Lippincott Journals

3. Deep Anterior Lamellar Keratoplasty (DALK)
   What: Replace diseased front cornea while sparing endothelium. Why: For deep deposits/haze with reduced vision when PTK is insufficient; recurrence can occur in the graft. PMC

4. Penetrating Keratoplasty (PK)
   What: Full-thickness corneal transplant. Why: Severe scarring or advanced haze. Caveat: Recurrence in the graft over time; requires long-term care. PubMed+1

5. Femtosecond-assisted Anterior Lamellar Keratoplasty
   What: Laser-crafted donor/host interfaces for precise lamellar grafts. Why: Improve fit and optical quality when layered surgery is planned. EyeWiki

---

Preventions

1. Avoid LASIK/PRK for refractive correction if you have GCD2 or a family history suggestive of it. PMC+1

2. Do genetic testing/counseling in at-risk families before any elective refractive procedure. Nature

3. Use preservative-free lubricants regularly to reduce friction. PMC

4. Nighttime gel/ointment to prevent morning erosions. PMC

5. Manage blepharitis/MGD (warm compresses, lid hygiene). PMC

6. Humidify your environment; wear moisture chamber eyewear in dry/windy settings. PMC

7. Avoid smoke/dust/irritants that destabilize the tear film. PMC

8. Prompt care for erosions, including a BCL if your doctor recommends it. PMC

9. Regular eye exams to track recurrence after PTK/keratoplasty. PubMed

10. Optimize systemic health & diet (hydration, omega-3s as appropriate) to support surface comfort. Office of Dietary Supplements

---

When to see a doctor

See an ophthalmologist promptly for: sharp pain, light sensitivity, sudden blur, foreign-body sensation, a visible open spot on the cornea, or any new haze after eye procedures. People with known or suspected GCD2 should seek specialist advice before any laser vision correction. After PTK or graft surgery, attend all follow-ups because recurrence is common and early retreatment keeps vision clearer. PubMed+1

---

What to eat and what to avoid

1. Eat: Fatty fish (EPA/DHA) 2–3×/week or fish-oil per clinician advice; may help dry-eye symptoms in some. Avoid: Oversupplementing without guidance. PubMed+1

2. Eat: Colorful vegetables and citrus (antioxidants/Vitamin C) to support healing. Avoid: Ultra-processed foods high in trans-fats. PMC

3. Drink: Adequate water daily. Avoid: Dehydration (caffeine/alcohol excess). PMC

4. Include: Nuts/seeds (balanced lipids). Avoid: Smoking (ocular surface irritant). ScienceDirect

5. Consider: Dietitian review if you have autoimmune dryness or meibomian issues. Avoid: High-sugar spikes that worsen systemic inflammation. PMC

---

FAQs

1. Is there a cure for GCD2?
   No. Current care eases symptoms and improves vision; recurrence is expected after laser or graft surgery. Research is ongoing. PMC+1

2. Will LASIK fix my vision if I have GCD2?
   No—LASIK can worsen GCD2. Avoid refractive laser if you or relatives have the condition. PMC+1

3. What surgery works best—PTK, DALK, or PK?
   Choice depends on depth and haze: PTK helps superficial disease but recurs; DALK/PK for deeper disease, with possible recurrence in grafts. PubMed+1

4. How fast does GCD2 come back after PTK?
   Recurrence can begin around 18–31 months on average, and repeat PTK may be needed. PubMed

5. Can special contact lenses help?
   Yes. Scleral lenses can vault over irregular corneas and improve vision/comfort. PMC

6. Are there medicines that stop the deposits?
   No approved drug halts deposits. Drops treat dry eye, inflammation, or infection risk; some biologics (e.g., cenegermin) help healing in neurotrophic corneas, not GCD2 itself. FDA Access Data

7. Will supplements cure GCD2?
   No. Supplements (e.g., omega-3s) may reduce dry-eye symptoms in some, but results are mixed; they don’t remove deposits. PubMed+1

8. Why do erosions hurt so much?
   Deposits and haze disrupt the epithelial anchoring; at night the lid sticks, then peels epithelium on waking—causing sharp pain and tearing. PMC

9. Can the disease skip people in a family?
   It is autosomal dominant; some carriers show mild or late changes, so genetic testing helps clarify risk. Nature

10. Will a corneal transplant last forever?
    Transplants can restore clarity, but GCD2 can recur in the graft over years. Lifelong follow-up is needed. PMC

11. Is PTK safe to repeat?
    Yes in selected eyes; many patients undergo re-PTK when haze recurs, with improvement in vision each time. Nature

12. Could I be asymptomatic and still have GCD2?
    Yes—some carriers are minimally symptomatic until triggered (e.g., surgery), which is why pre-LASIK screening matters. PMC

13. Does GCD2 affect life expectancy or cause blindness?
    It doesn’t affect life expectancy. It rarely causes complete blindness, but can seriously reduce vision without treatment. PMC

14. Are there new treatments coming?
    Preclinical models (e.g., R124H TGFBI mouse) and molecular studies aim to target the abnormal protein pathway; clinical gene or protein therapies are not yet available. PLOS+1

15. What’s the single most important safety tip?
    If GCD2 is suspected in you or family, avoid refractive laser surgery and get specialist advice. JAMA Network

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 14, 2025.